XINTELA AB (PUBL)
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors.
XINTELA AB (PUBL)
Industry:
Alternative Medicine Biotechnology Health Care Medical
Founded:
2009-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.xintela.se
Total Employee:
11+
Status:
Active
Contact:
556780-3480
Email Addresses:
[email protected]
Total Funding:
6 M SEK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Domain Not Resolving Apache Amazon
Similar Organizations
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
VectivBio
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Almi Invest
Almi Invest investment in Venture Round - Xintela AB (publ)
Official Site Inspections
http://www.xintela.se
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Xintela AB (publ)"
About Xintela | Xintela AB
Xintela is a biopharma company that develops stem cell-based treatments focusing on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive …See details»
Research and Development | Xintela AB
Research in Xintela's subsidiary Targinta has in recent years shown that integrin α10β1 is also found in certain aggressive cancer cells such as in triple-negative breast cancer and the brain tumor glioblastoma, which is the reason for …See details»
Xintela AB (publ) - Org Chart, Teams, Culture & Jobs - The Org
View Xintela AB (publ)'s up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Xintela AB (publ) - Crunchbase Company Profile & Funding
Organization. Xintela AB (publ) Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone …See details»
Xintela AB Company Profile | Lund, Skåne, Sweden | Competitors ...
Find company research, competitor information, contact details & financial data for Xintela AB of Lund, Skåne. Get the latest business insights from Dun & Bradstreet.See details»
Xintela AB | LinkedIn
Xintela AB | 2 421 följare på LinkedIn. Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and …See details»
Xintela AB, Financial Info, Board and Management, Remuneration
Market Cap (EUR) NOTES: †- Upcoming company / Assignment in upcoming company ♘ - Unicorn company Δ - Growth company â„— - Portfolio company ň - New company …See details»
Xintela AB (publ) (STO: XINT) Company Profile & Overview - Stock …
Nov 19, 2024 Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include …See details»
Xintela expands and strengthens management team
Aug 19, 2020 Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: [email protected] Medicon Village 223 81 Lund, Sweden www.xintela.se . About Xintela. Xintela …See details»
Xintela Company Profile - Office Locations, Competitors ... - Craft
Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure stem cells for the treatment …See details»
Xintela - Products, Competitors, Financials, Employees, …
Stem Cell Cartilage Regeneration Market See Incredible Growth 2023-2030 | Xintela AB, CellGenix GmbH, Merck KGaA, News Provided By Share This Article Stem Cell Cartilage …See details»
Xintela Company Profile 2024: Stock Performance & Earnings
Xintela General Information Description. Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, …See details»
Xintela: Xintela GMP inspection for manufacturing license ... - Placera
Apr 12, 2021 Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology …See details»
Xintela: Activities below the surface - Placera
Sep 3, 2024 Xintela recently extended the follow-up of the patients in the highest dose level group by six months in its OA study. The company expects an interim analysis from the 18 …See details»
Investors | Xintela AB
Xintela AB (publ) is listed at Nasdaq First North Growth Market Stockholm per 2016-03-22. Xintela's shares are traded under the name XINT (ISIN SE0007756903). Following the latest …See details»
Xintela’s CEO sees potential in difficult-to-heal wounds
Apr 12, 2022 Xintela’s CEO Evy Lundgren-Åkerlund emphasises the medical need in difficult-to-heal wounds in a press release: »Wound healing is an exciting indication for our stem cell …See details»
News and media | Xintela AB
Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: …See details»
Xintela: Awaiting results in trials and discussions | Placera
Feb 29, 2024 Xintela reported a negative cash flow of SEK 11.6 million for the quarter and had a cash balance of SEK 7.8 million at the end of the year. Despite the financial situation, we still …See details»
Press releases | Xintela AB
Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: …See details»